AstraZeneca PLC (AZNCF) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Cambridge, イギリス. 現CEOは Pascal Claude Roland Soriot.
AZNCF を有する IPO日 2009-02-13, 94,300 名の正社員, に上場 Other OTC, 時価総額 $294.4B.
AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom, specializing in the discovery, development, manufacturing, and commercialization of prescription medicines. The company maintains a diverse portfolio spanning oncology, cardiovascular and metabolic diseases, respiratory and immunology, and rare diseases, with marketed products including Tagrisso, Lynparza, and Imfinzi for cancer; Farxiga and Crestor for heart and metabolic conditions; Symbicort and Fasenra for respiratory care; and Soliris for rare diseases, among many others. AstraZeneca also markets vaccines and treatments for respiratory syncytial virus, influenza, COVID-19, and other therapeutic areas. The company distributes its medicines through a global network of physicians and representatives across Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca maintains strategic collaborations with leading pharmaceutical and biotechnology partners, including Regeneron Pharmaceuticals for obesity treatments and Ionis Pharmaceuticals for antisense therapies in development.
